Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
Identifieur interne : 000232 ( Main/Exploration ); précédent : 000231; suivant : 000233Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
Auteurs : Jae Brimhall [États-Unis] ; Malhar A. Jhaveri ; Juan F. YepesSource :
- Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry [ 1754-4505 ]
Descripteurs français
- KwdFr :
- Agonistes muscariniques (effets indésirables), Agonistes muscariniques (pharmacologie), Analyse de variance (MeSH), Humains (MeSH), Larmes (métabolisme), Loi du khi-deux (MeSH), Mâle (MeSH), Méthode en double aveugle (MeSH), Personnes se prêtant à la recherche (psychologie), Pilocarpine (effets indésirables), Pilocarpine (pharmacologie), Projets pilotes (MeSH), Quinuclidines (effets indésirables), Quinuclidines (pharmacologie), Salivation (effets des médicaments et des substances chimiques), Statistique non paramétrique (MeSH), Sudation (MeSH), Thiophènes (effets indésirables), Thiophènes (pharmacologie), Xérostomie (traitement médicamenteux), Études croisées (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Salivation.
- effets indésirables : Agonistes muscariniques, Pilocarpine, Quinuclidines, Thiophènes.
- métabolisme : Larmes.
- pharmacologie : Agonistes muscariniques, Pilocarpine, Quinuclidines, Thiophènes.
- psychologie : Personnes se prêtant à la recherche.
- traitement médicamenteux : Xérostomie.
- Analyse de variance, Humains, Loi du khi-deux, Mâle, Méthode en double aveugle, Projets pilotes, Statistique non paramétrique, Sudation, Études croisées.
English descriptors
- KwdEn :
- Analysis of Variance (MeSH), Chi-Square Distribution (MeSH), Cross-Over Studies (MeSH), Double-Blind Method (MeSH), Humans (MeSH), Male (MeSH), Muscarinic Agonists (adverse effects), Muscarinic Agonists (pharmacology), Pilocarpine (adverse effects), Pilocarpine (pharmacology), Pilot Projects (MeSH), Quinuclidines (adverse effects), Quinuclidines (pharmacology), Research Subjects (psychology), Salivation (drug effects), Statistics, Nonparametric (MeSH), Sweating (MeSH), Tears (metabolism), Thiophenes (adverse effects), Thiophenes (pharmacology), Xerostomia (drug therapy).
- MESH :
- chemical , adverse effects : Muscarinic Agonists, Pilocarpine, Quinuclidines, Thiophenes.
- chemical , pharmacology : Muscarinic Agonists, Pilocarpine, Quinuclidines, Thiophenes.
- drug effects : Salivation.
- drug therapy : Xerostomia.
- metabolism : Tears.
- psychology : Research Subjects.
- Analysis of Variance, Chi-Square Distribution, Cross-Over Studies, Double-Blind Method, Humans, Male, Pilot Projects, Statistics, Nonparametric, Sweating.
Abstract
OBJECTIVES
To determine the efficacy and compare the side-effects of cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia.
METHODS
A randomized, cross-over, double blind study was designed. Fifteen patients with diagnosis of xerostomia were assigned to take either 5 mg of pilocarpine or 30 mg of cevimeline three times a day for four weeks. Salivary flow rates were measured during the initial baseline, first and second month appointments. Statistical analysis was carried out with ANOVA and post hoc t-tests.
RESULTS
Twelve patients completed both medication treatments. Although both medications proved to increase salivary secretion, there was no significant difference between pilocarpine and cevimeline. Also, the perceived side-effects between the two medications were similar.
CONCLUSION
Both medications increased the secretion of saliva at the end of four weeks. However, there was a slightly higher increment in saliva with pilocarpine. However, the difference was not statistically significant.
DOI: 10.1111/scd.12010
PubMed: 23600983
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.</title><author><name sortKey="Brimhall, Jae" sort="Brimhall, Jae" uniqKey="Brimhall J" first="Jae" last="Brimhall">Jae Brimhall</name><affiliation wicri:level="2"><nlm:affiliation>Orthodontics Resident, University of Kentucky College of Dentistry, Lexington, Kentucky, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orthodontics Resident, University of Kentucky College of Dentistry, Lexington, Kentucky</wicri:regionArea><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Jhaveri, Malhar A" sort="Jhaveri, Malhar A" uniqKey="Jhaveri M" first="Malhar A" last="Jhaveri">Malhar A. Jhaveri</name></author><author><name sortKey="Yepes, Juan F" sort="Yepes, Juan F" uniqKey="Yepes J" first="Juan F" last="Yepes">Juan F. Yepes</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013 May-Jun</date><idno type="RBID">pubmed:23600983</idno><idno type="pmid">23600983</idno><idno type="doi">10.1111/scd.12010</idno><idno type="wicri:Area/Main/Corpus">000243</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000243</idno><idno type="wicri:Area/Main/Curation">000243</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000243</idno><idno type="wicri:Area/Main/Exploration">000243</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.</title><author><name sortKey="Brimhall, Jae" sort="Brimhall, Jae" uniqKey="Brimhall J" first="Jae" last="Brimhall">Jae Brimhall</name><affiliation wicri:level="2"><nlm:affiliation>Orthodontics Resident, University of Kentucky College of Dentistry, Lexington, Kentucky, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orthodontics Resident, University of Kentucky College of Dentistry, Lexington, Kentucky</wicri:regionArea><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Jhaveri, Malhar A" sort="Jhaveri, Malhar A" uniqKey="Jhaveri M" first="Malhar A" last="Jhaveri">Malhar A. Jhaveri</name></author><author><name sortKey="Yepes, Juan F" sort="Yepes, Juan F" uniqKey="Yepes J" first="Juan F" last="Yepes">Juan F. Yepes</name></author></analytic><series><title level="j">Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry</title><idno type="eISSN">1754-4505</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance (MeSH)</term><term>Chi-Square Distribution (MeSH)</term><term>Cross-Over Studies (MeSH)</term><term>Double-Blind Method (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Muscarinic Agonists (adverse effects)</term><term>Muscarinic Agonists (pharmacology)</term><term>Pilocarpine (adverse effects)</term><term>Pilocarpine (pharmacology)</term><term>Pilot Projects (MeSH)</term><term>Quinuclidines (adverse effects)</term><term>Quinuclidines (pharmacology)</term><term>Research Subjects (psychology)</term><term>Salivation (drug effects)</term><term>Statistics, Nonparametric (MeSH)</term><term>Sweating (MeSH)</term><term>Tears (metabolism)</term><term>Thiophenes (adverse effects)</term><term>Thiophenes (pharmacology)</term><term>Xerostomia (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agonistes muscariniques (effets indésirables)</term><term>Agonistes muscariniques (pharmacologie)</term><term>Analyse de variance (MeSH)</term><term>Humains (MeSH)</term><term>Larmes (métabolisme)</term><term>Loi du khi-deux (MeSH)</term><term>Mâle (MeSH)</term><term>Méthode en double aveugle (MeSH)</term><term>Personnes se prêtant à la recherche (psychologie)</term><term>Pilocarpine (effets indésirables)</term><term>Pilocarpine (pharmacologie)</term><term>Projets pilotes (MeSH)</term><term>Quinuclidines (effets indésirables)</term><term>Quinuclidines (pharmacologie)</term><term>Salivation (effets des médicaments et des substances chimiques)</term><term>Statistique non paramétrique (MeSH)</term><term>Sudation (MeSH)</term><term>Thiophènes (effets indésirables)</term><term>Thiophènes (pharmacologie)</term><term>Xérostomie (traitement médicamenteux)</term><term>Études croisées (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Muscarinic Agonists</term><term>Pilocarpine</term><term>Quinuclidines</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Muscarinic Agonists</term><term>Pilocarpine</term><term>Quinuclidines</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Xerostomia</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Salivation</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agonistes muscariniques</term><term>Pilocarpine</term><term>Quinuclidines</term><term>Thiophènes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Tears</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Larmes</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agonistes muscariniques</term><term>Pilocarpine</term><term>Quinuclidines</term><term>Thiophènes</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Personnes se prêtant à la recherche</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Research Subjects</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Xérostomie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Chi-Square Distribution</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Pilot Projects</term><term>Statistics, Nonparametric</term><term>Sweating</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de variance</term><term>Humains</term><term>Loi du khi-deux</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Projets pilotes</term><term>Statistique non paramétrique</term><term>Sudation</term><term>Études croisées</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To determine the efficacy and compare the side-effects of cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A randomized, cross-over, double blind study was designed. Fifteen patients with diagnosis of xerostomia were assigned to take either 5 mg of pilocarpine or 30 mg of cevimeline three times a day for four weeks. Salivary flow rates were measured during the initial baseline, first and second month appointments. Statistical analysis was carried out with ANOVA and post hoc t-tests.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Twelve patients completed both medication treatments. Although both medications proved to increase salivary secretion, there was no significant difference between pilocarpine and cevimeline. Also, the perceived side-effects between the two medications were similar.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Both medications increased the secretion of saliva at the end of four weeks. However, there was a slightly higher increment in saliva with pilocarpine. However, the difference was not statistically significant.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23600983</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1754-4505</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>3</Issue><PubDate><MedlineDate>2013 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry</Title><ISOAbbreviation>Spec Care Dentist</ISOAbbreviation></Journal><ArticleTitle>Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.</ArticleTitle><Pagination><MedlinePgn>123-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/scd.12010</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the efficacy and compare the side-effects of cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, cross-over, double blind study was designed. Fifteen patients with diagnosis of xerostomia were assigned to take either 5 mg of pilocarpine or 30 mg of cevimeline three times a day for four weeks. Salivary flow rates were measured during the initial baseline, first and second month appointments. Statistical analysis was carried out with ANOVA and post hoc t-tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve patients completed both medication treatments. Although both medications proved to increase salivary secretion, there was no significant difference between pilocarpine and cevimeline. Also, the perceived side-effects between the two medications were similar.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Both medications increased the secretion of saliva at the end of four weeks. However, there was a slightly higher increment in saliva with pilocarpine. However, the difference was not statistically significant.</AbstractText><CopyrightInformation>©2013 Special Care Dentistry Association and Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brimhall</LastName><ForeName>Jae</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Orthodontics Resident, University of Kentucky College of Dentistry, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Malhar A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Yepes</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Spec Care Dentist</MedlineTA><NlmUniqueID>8103755</NlmUniqueID><ISSNLinking>0275-1879</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011812">Quinuclidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>01MI4Q9DI3</RegistryNumber><NameOfSubstance UI="D010862">Pilocarpine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K9V0CDQ56E</RegistryNumber><NameOfSubstance UI="C059240">cevimeline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>D</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010862" MajorTopicYN="N">Pilocarpine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011812" MajorTopicYN="N">Quinuclidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035842" MajorTopicYN="N">Research Subjects</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012472" MajorTopicYN="N">Salivation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013546" MajorTopicYN="N">Sweating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013666" MajorTopicYN="N">Tears</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014987" MajorTopicYN="N">Xerostomia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23600983</ArticleId><ArticleId IdType="doi">10.1111/scd.12010</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Kentucky</li></region></list><tree><noCountry><name sortKey="Jhaveri, Malhar A" sort="Jhaveri, Malhar A" uniqKey="Jhaveri M" first="Malhar A" last="Jhaveri">Malhar A. Jhaveri</name><name sortKey="Yepes, Juan F" sort="Yepes, Juan F" uniqKey="Yepes J" first="Juan F" last="Yepes">Juan F. Yepes</name></noCountry><country name="États-Unis"><region name="Kentucky"><name sortKey="Brimhall, Jae" sort="Brimhall, Jae" uniqKey="Brimhall J" first="Jae" last="Brimhall">Jae Brimhall</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000232 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000232 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23600983
|texte= Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23600983" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |